Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2018 · 10-Q
Revenue$100.14K$100.14K+5.4% vs Q1 2017 Net Income-$4.79M-$4.79MN/M vs Q1 2017 EPS Diluted-$6.23-$6.23N/M vs Q1 2017 Operating Income-$4,655,023N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,861,247N/M Margins · derivedOperating margin-4648.7%+6005.6 pt vs Q1 2017
Net margin-4779.7%+5741.9 pt vs Q1 2017
ended Mar 31, 2018 · filed May 8, 2018 · 38 d after period end